

CLAIMS

1. A nucleic acid capable of being specifically bound to a target protein of Ras.

2. The nucleic acid as claimed in claim 1, which nucleic acid is an RNA.

3. The nucleic acid as claimed in claim 1 or 2, which nucleic acid is specifically bound to a Ras binding domain of the target protein of Ras.

4. The nucleic acid as claimed in any of claims 1 to 3, wherein the target protein of Ras is Raf-1.

5. The nucleic acid as claimed in claim 4, which nucleic acid is an RNA that is specifically bound to a Ras binding domain (RBD) of Raf-1.

6. The nucleic acid as claimed in any of claims 2 to 4, wherein the RNA is an RNA containing at least any one of base sequences of sequence Nos. 1 to 28 of Sequence Listing or a base sequence in which at least one base thereof is deleted and substituted with another base and/or at least one base is added.

7. (amended) The nucleic acid as claimed in claim 6, wherein the RNA is an RNA containing at least any one of base sequences of sequence Nos. 1 to 8 or sequence Nos. 25 to 28 of Sequence Listing or a base sequence in which at least one base thereof is deleted and substituted with another base and/or at least one base is added.

8. A nucleic acid having a complementary base sequence

to the nucleic acid as claimed in claim 6 or 7.

9. An agent for controlling cell signal transduction which agent is made of the nucleic acid as claimed in any of claims 1 to 8.

10. The controlling agent as claimed in claim 9, wherein the nucleic acid is an RNA.

11. (added) A method of controlling cell signal transduction using the nucleic acid as claimed in any of claims 1 to 8.

12. (amended) The method as claimed in claim 11, wherein the nucleic acid is an RNA.

13. (amended) A pharmaceutical composition containing the nucleic acid as claimed in any of claims 1 to 8.

14. (amended) The pharmaceutical composition as claimed in claim 13, which composition is used for treating cancers or inflammatory diseases.

15. (amended) A method of selecting an RNA having an ability of specific binding to a target protein of Ras, which comprises selecting the RNA having the ability of specific binding to the target protein of Ras from an RNA pool having various base sequences.

16. (amended) The method as claimed in claim 15, wherein the RNA of the RNA pool having various base sequences is an RNA comprising 20 to 300 bases.

17. (amended) The method as claimed in claim 15 or 16,

wherein the target protein of Ras is Raf-1.

18. (deleted)

add
a

009260 60262360